- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Xetra | 90,530 | 04.06.24 17:35:32 | +0,480 | +0,53% | 0,000 | 0,000 | 90,060 | 90,050 |
|
Regeneron Pharmaceuticals | 881535 | NASDAQ | 994,285 | 04.06.24 21:52:09 | +4,805 | +0,49% | 994,260 | 995,000 | 980,160 | 989,480 |
